Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Hepatology (Liver, Pancreatic, Gall Bladder) | Infections and Infectious Diseases | Vaccines
Hepatitis Clinical Trials
A listing of Hepatitis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : 1220.48.0045 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Birmingham : 1220.48.0004 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Birmingham :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Birmingham : Site Reference ID/Investigator# 78884
A Study to Evaluate Chronic Hepatitis C Infection
Birmingham :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
View More »
Birmingham : Site Reference ID/Investigator# 86346
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Birmingham :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Birmingham : University of Alabama at Birmingham
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Birmingham : University Of Alabama At Birmingham
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Dothan : Digestive Health Specialists
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Dothan : Site Reference ID/Investigator# 78856
A Study to Evaluate Chronic Hepatitis C Infection
Dothan : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Dothan : Digestive Health Specialists
Gilead Sustained Virologic Response (SVR) Registry
Huntsville : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Montgomery : Alabama Liver & Digestive Specialists (Alds)
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Montgomery : Alabama Liver & Digestive Specialists (Alds)
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Montgomery : Alabama Liver & Digestive Specialists (Alds)
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Arizona
Goodyear : Call for Information (Investigational Site 0118)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Phoenix : Call for Information (Investigational Site 0164)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Phoenix : Mayo Clinic Hospital
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Tucson : Site Reference ID/Investigator# 70141
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Arkansas
Little Rock :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
North Little Rock : 1220.48.0091 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
North Little Rock : 1241.36.00016 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
California
Anaheim : Anaheim Clinical Trials (ACT)
Hepatitis C research study for Latino and non-Latino patients who are treatment Naïve.
View More »
Anaheim : Advanced Clinical Research Institute, LLC
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Anaheim : Call for Information (Investigational Site 0363)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Anaheim : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Anaheim : Advanced Clinical Research Institute, LLC
Gilead Sustained Virologic Response (SVR) Registry
Anaheim : Anaheim Clinical Trials Llc
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Bakersfield : 1220.48.0008 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bakersfield : Call for Information (Investigational Site 0121)
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Bakersfield :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Bakersfield : Site Reference ID/Investigator# 78848
A Study to Evaluate Chronic Hepatitis C Infection
Bakersfield : Site Reference ID/Investigator# 72455
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bakersfield : Dr. Franco Felizarta
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Bakersfield : Franco Felizarta, MD
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Bakersfield : 1241.36.00005 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Bakersfield : Call for Information (Investigational Site 0412)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Beverly Hills : California Liver Institute
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Beverly Hills : California Liver Institute
Gilead Sustained Virologic Response (SVR) Registry
Chula Vista : 1241.20.00033 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Chula Vista : Call for Information (Investigational Site 0159)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Coronado : 1220.48.0010 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Coronado : Site Reference ID/Investigator# 78701
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Coronado : Southern California Transplantation Institute, Research Foundation Liver Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Costa Mesa : West Coast Clinical Trials, LLC
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Escondido : 1241.36.00013 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Garden Grove : Sc Clinical Research, Inc.
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Irvine : Call for Information (Investigational Site 0152)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
La Jolla :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
La Jolla : 1241.36.00009 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
La Jolla : Scripps Clinical Research Center
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
La Jolla : 1241.21.0003 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
La Jolla : Scripps Clinic
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
La Jolla : Scripps Clinic
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
La Mesa : 1220.48.0035 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
La Mesa : 1241.20.00006 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
La Mesa : eStudy Site
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Lajolla : Scripps Clinic
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Loma Linda :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Long Beach : Call for Information (Investigational Site 0355)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Los Angeles : California Liver Institute
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Los Angeles : 1220.48.0011 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Los Angeles :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Los Angeles : Site Reference ID/Investigator# 86120
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Los Angeles : Site Reference ID/Investigator# 86336
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Los Angeles : Health Care Consultants
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Los Angeles : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Los Angeles :
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Los Angeles : California Liver Institute
Gilead Sustained Virologic Response (SVR) Registry
Los Angeles : Anthony Mills MD, Inc.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Los Angeles : Cedars-Sinai Medical Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Los Angeles : Kaiser Permanente
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Los Angeles : Lightsource Medical/Peter J. Ruane MD, Inc.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Los Angeles : Kaiser Permanente Los Angeles Medical Center
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Los Angeles : Scpmg/ Kaiser Permanente Los Angeles Medical Center
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Los Angeles : Call for Information (Investigational Site 0405)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Los Angeles : Southern California Permanente Medical Group
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Los Angeles :
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Los Angeles : Scpmg/ Kaiser Permanente Los Angeles Medical Center
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Oceanside : 1220.48.0018 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Oceanside : 1241.20.00003 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Oceanside : eStudySite
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Palm Springs : Desert Medical Group Inc.
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Palo Alto : Stanford University
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy While on the Orthotopic Liver Transplant (OLT) List
Pasadena :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Poway : 1241.20.00008 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Riverside : Call for Information (Investigational Site 0144)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Sacramento :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Sacramento : University Of California Davis Medical Center
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Sacramento : Call for Information (Investigational Site 0169)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Sacramento : Call for Information (Investigational Site 0176)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
San Diego : Medical Associates Research Group, Inc.
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
San Diego : Research and Education Inc.
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
San Diego : University of California Antiviral Research Center (AVRC)
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
San Diego : University of California Antiviral Research Center (AVRC)
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
San Diego :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
San Diego : Site Reference ID/Investigator# 78838
A Study to Evaluate Chronic Hepatitis C Infection
San Diego :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
San Diego : Site Reference ID/Investigator# 84474
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
San Diego :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
San Diego : Medical Associates Research Group, Inc.
Gilead Sustained Virologic Response (SVR) Registry
San Diego : Medical Associates Research Group
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
San Diego : Kaiser Permanente
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
San Diego : 1241.36.00019 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
San Diego :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
San Diego : Ucsd Antiviral Research Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Diego : 1241.21.0006 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
San Diego : Research And Education, Inc.
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
San Francisco : University Of California, San Francisco
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
San Francisco : 1220.48.0031 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
San Francisco : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
San Francisco : Quest Clinical Research
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
San Francisco :
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
San Francisco : San Francisco General Hospital
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco : Kaiser Permanente Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Francisco : 1241.21.0004 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
San Francisco :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Simi Valley : Call for Information (Investigational Site 0407)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Torrance :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Ventura : Call for Information (Investigational Site 0408)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Colorado
Aurora : University of Colorado
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Aurora : Site Reference ID/Investigator# 78754
A Study to Evaluate Chronic Hepatitis C Infection
Aurora :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Aurora :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Aurora : University of Colorado
Gilead Sustained Virologic Response (SVR) Registry
View More »
Aurora :
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Aurora : University of Colorado Hospital
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Aurora : University of Colorado Hospital
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Aurora : University Of Colorado
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Aurora : University Of Colorado Denver And Hospital
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Aurora : University Of Colorado Denver And Hospital
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Aurora : University Of Colorado Denver And Hospital
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Aurora : University Of Colorado Denver & Hospital
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Denver : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Englewood : South Denver Gastroenterology
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Englewood : Call for Information (Investigational Site 0349)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Englewood :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Englewood : South Denver Gastroenterology
Gilead Sustained Virologic Response (SVR) Registry
Englewood : South Denver Gastroenterology, PC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Englewood :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Lakewood : Site Reference ID/Investigator# 78697
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Littleton : Site Reference ID/Investigator# 70140
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Connecticut
Hartford : Connecticut Children'S Medical Center
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
New Haven :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
New Haven : Yale University School Of Medicine
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
New Haven : Yale University School Of Medicine
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
New Haven : Yale University School Of Medicine
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
View More »
New Haven : Yale University School Of Medicine
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Torrington :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
West Haven : Va Connecticut Healthcare System
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
District of Columbia
Washington : Children'S National Medical Center
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Washington : Site Reference ID/Investigator# 78844
A Study to Evaluate Chronic Hepatitis C Infection
Washington : Georgetown University Hospital
Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
Washington : Whitman-Walker Health
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Washington :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
View More »
Washington : Georgetown University Hospital
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Florida
Bradenton : University Hepatitis Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Bradenton :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Bradenton :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Bradenton : University Hepatitis Center
Gilead Sustained Virologic Response (SVR) Registry
Bradenton : Bach and Godofsky MD, PA
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
View More »
Bradenton : 1241.36.00022 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Brandenton :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Daytona Beach :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Deland :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
DeLand : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Deland : 1241.36.00004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Deland : Avail Clinical Research, LLC
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Fort Lauderdale : 1220.48.0078 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Fort Lauderdale : Therafirst Medical Centers
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Fort Lauderdale : 1241.20.00015 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Fort Lauderdale : 1241.36.00006 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Fort Pierce : Site Reference ID/Investigator# 78874
A Study to Evaluate Chronic Hepatitis C Infection
Fort Pierce : 1241.20.00014 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Gainesville : University Of Florida
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Gainesville : Site Reference ID/Investigator# 78868
A Study to Evaluate Chronic Hepatitis C Infection
Gainesville : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Gainesville : University of Florida
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Gainesville : University Of Florida Hepatology
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Gainesville : University Of Florida Hepatology
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Jacksonville : Borland-Groover Clinic Baptist
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Jacksonville : Site Reference ID/Investigator# 78690
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Jacksonville :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Jacksonville : Borland-Groover Clinic Baptist
Gilead Sustained Virologic Response (SVR) Registry
Jacksonville : Borland-Groover Clinic
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Largo :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Maitland :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Maitland : 1241.20.00004 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Miami :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Miami : Call for Information (Investigational Site 0366)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Miami : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Miami : University of Miami Center for Liver Diseases
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Miami : Call for Information (Investigational Site 0163)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Miami : University Of Miami School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Miami : University Of Miami
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
New Port Richey : Advanced Research Institute, Inc.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Orlando : Orlando Clinical Research Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Orlando : Orlando Immunology Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Orlando : 1220.48.0044 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Orlando :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Orlando :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Orlando :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Orlando : Site Reference ID/Investigator# 86124
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Orlando : Site Reference ID/Investigator# 78676
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Orlando :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Orlando : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Orlando : Orlando Clinical Research Center
Gilead Sustained Virologic Response (SVR) Registry
Orlando : Orlando Immunology Center (ACH)
Gilead Sustained Virologic Response (SVR) Registry
Orlando : Internal Medicine Specialists
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Orlando : Orlando Immunology Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Orlando : Orlando Clinical Research Center
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Orlando : 1241.36.00010 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Orlando :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Orlando : Orlando Immunology Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Orlando : Orlando Clinical Research Center
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Orlando : Call for Information (Investigational Site 0003)
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172 (MK-5172-013 AM3)
Palm Harbor : 1220.48.0095 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Palm Harbor : 1241.36.00024 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Palm Harbor : 1241.21.0011 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
South Miami : Miami Research Associates
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Tampa :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Tampa :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Tampa :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Tampa : Tampa General Hospital
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Tampa : Call for Information (Investigational Site 0166)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Wellington : South Florida Center of Gastroenterology, P.A.
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Wellington :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Wellington : Site Reference ID/Investigator# 79493
A Study to Evaluate Chronic Hepatitis C Infection
Wellington : South Florida Center of Gastroenterology, P.A.
Gilead Sustained Virologic Response (SVR) Registry
Wellington : South Florida Center of Gastroenterology, PA.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Wellington :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Zephyrhills : Site Reference ID/Investigator# 78843
A Study to Evaluate Chronic Hepatitis C Infection
Georgia
Atlanta : Romero, Rene
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Atlanta :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Atlanta :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Atlanta : Site Reference ID/Investigator# 78695
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Atlanta : Atlanta Gastroenterology Associates
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
View More »
Atlanta :
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Atlanta : Atlanta Gastroenterology Associates, LLC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Atlanta : Digestive Healthcare of Georgia
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Atlanta : Call for Information (Investigational Site 0132)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Atlanta :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Columbus : 1220.48.0039 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Columbus : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Decatur : Atlanta Infectious Disease Specialists
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Decatur : Dekalb Gastroenterology Associates
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Decatur :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Decatur : Atlanta Infectious Disease Specialists
Gilead Sustained Virologic Response (SVR) Registry
Decatur : Dekalb Gastroenterology Associates
Gilead Sustained Virologic Response (SVR) Registry
Decatur :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Douglasville : American Red Cross
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Macon :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Marietta : Gastrointestinal Specialists of Georgia, PC
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Marietta : Georgia
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
Marietta :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Marietta :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Marietta : Dr. Aasim Sheikh
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Marietta : Gastrointestinal Specialists of Georgia, PC
Gilead Sustained Virologic Response (SVR) Registry
Marietta : Gastointestinal Specialists of Georgia, PC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Marietta : Gastrointestinal Specialists Of Georgia Pc
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Marietta :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Savannah : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Hawaii
Honolulu : Site Reference ID/Investigator# 70152
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Idaho
Boise : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Illinois
Chicago : 1220.48.0013 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Chicago :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Chicago : Site Reference ID/Investigator# 79093
A Study to Evaluate Chronic Hepatitis C Infection
Chicago :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Chicago :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
View More »
Chicago :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Springfield : Call for Information (Investigational Site 0135)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Indiana
Indianapolis : Indiana University School Of Medicine / Riley Hospital
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Indianapolis : Indiana University Medical Center
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Indianapolis : Indiana University Medical Center
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Indianapolis :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Indianapolis :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
View More »
Indianapolis : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Indianapolis : Call for Information (Investigational Site 0150)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Indianapolis :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Indianapolis :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Mishawaka : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Valparaiso : 1241.36.00001 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Valparaiso : 1241.21.0013 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Kansas
Kansas City :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Overland Park :
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
Wichita : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Kentucky
Bowling Green : Graves-Gilbert Clinic
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Bowling Green : Graves-Gilbert Clinic
Gilead Sustained Virologic Response (SVR) Registry
Crestview Hills :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Louisville : Call for Information (Investigational Site 0393)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Pikeville : Call for Information (Investigational Site 0117)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Louisiana
Baton Rouge : Gastroenterology Associates, LLC
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Baton Rouge : 1220.48.0085 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Baton Rouge : 1220.48.0087 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Baton Rouge : Gastroenterology Associates, LLC
Gilead Sustained Virologic Response (SVR) Registry
Metairie :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
View More »
New Orleans : 1220.48.0101 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
New Orleans : Tulane University Health Sciences Center
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
New Orleans : Tulane University Health Sciences Center
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
New Orleans :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Shreveport : Site Reference ID/Investigator# 78835
A Study to Evaluate Chronic Hepatitis C Infection
Shreveport : Site Reference ID/Investigator# 78677
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Maryland
Annapolis : Site Reference ID/Investigator# 78689
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Annapolis : Site Reference ID/Investigator# 72454
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Baltimore : University of Maryland Institute of Human Virology
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Baltimore : Johns Hopkins School Of Medicine
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Baltimore : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
View More »
Baltimore : Site Reference ID/Investigator# 78735
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Baltimore : Site Reference ID/Investigator# 70151
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Baltimore :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Baltimore : Evelyn Jordan Center
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Baltimore : University of Maryland, School of Medicine
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Baltimore : Mercy Medical Center
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Baltimore : Johns Hopkins Drug Development Unit
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Baltimore : Digestive Disease Associates, PA
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Baltimore : Call for Information (Investigational Site 0404)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Baltimore :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Baltimore : Mercy Medical Center, Inc.
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Baltimore : Mercy Medical Center
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Baltimore : Digestive Disease Associates, P.A.
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Baltimore : Mercy Medical Center
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Bethesda : NIH Department of Laboratory Medicine
A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
Bethesda : National Institute of Allergy and Infectious Diseases
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Bethesda : National Institute of Allergy and Infectious Diseases
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Colombia : Gastro Center Of Maryland
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Lutherville :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Lutherville : Johns Hopkins University
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Lutherville : Johns Hopkins University
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Lutherville : Johns Hopkins University
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Massachusetts
Boston : Beth Israel Deaconess Medical Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Boston : Children'S Hospital Of Boston
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Boston : Shah, Uzma
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Boston : Beth Israel Deaconess Medical Center
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Boston : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
View More »
Boston : Beth Israel Deaconess Medical Center
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
Boston : BIDMC
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Boston : Beth Israel Deaconess Medical Center
Gilead Sustained Virologic Response (SVR) Registry
Boston :
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Boston : Beth Israel Deaconess Medical Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Boston : Massachusetts General Hospital
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Boston : Call for Information (Investigational Site 0002)
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (SCH503034-P07614 AM6)
Boston : Beth Israel Deaconess Medical Center
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Boston : Massachusetts General Hospital
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy While on the Orthotopic Liver Transplant (OLT) List
Boston : Massachusetts General Hospital
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Boston :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Brockton : Commonwealth Clinical Studies, LLC
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Brockton :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Brockton : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Brockton : Commonwealth Clinical Studies, LLC
Gilead Sustained Virologic Response (SVR) Registry
Framingham : 1220.48.0027 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Springfield : 1220.48.0065 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Springfield :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Springfield : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Springfield : Infectious Disease and The Research Institute
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Springfield : 1241.21.0008 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Worcester :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Michigan
Ann Arbor :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Detroit : Henry Ford Health System
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Detroit : Henry Ford Health System
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Detroit : Henry Ford Health System
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Detroit : Site Reference ID/Investigator# 78852
A Study to Evaluate Chronic Hepatitis C Infection
View More »
Detroit :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Detroit :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Detroit : Henry Ford Hospital
Association Between Hepatitis C Infection and Renal Cell Carcinoma
Detroit : Henry Ford Health System
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Detroit : Henry Ford Health System
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Detroit :
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
Detroit : Henry Ford Health System
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Detroit : Henry Ford Health System
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Detroit : Henry Ford Health System
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Wyoming :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Minnesota
Minneapolis : University Of Minnesota
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Minneapolis :
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Rochester :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Rochester :
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Rochester :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
View More »
Rochester : Mayo Clinic
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
St. Paul : Prism Research
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
St. Paul : Site Reference ID/Investigator# 79497
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
St. Paul : Minnesota Gastroenterology, P.A.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Mississippi
Jackson : G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
3 Grams Daily Valacyclovir in Chronic Hepatitis C Infection (Phase II)
Jackson : Site Reference ID/Investigator# 78877
A Study to Evaluate Chronic Hepatitis C Infection
Jackson : G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
Jackson : G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS
Herpes Simplex Type 1 Suppression in Hepatitis C
Tupelo : Digestive Health Specialists
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
View More »
Tupelo : 1220.48.0023 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Tupelo :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Tupelo : Digestive Health Specialists
Gilead Sustained Virologic Response (SVR) Registry
Tupelo : 1241.36.00018 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Missouri
Kansas City : Kansas City Gastroenterology and Hepatology
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Kansas City : Kansas City Gastroenterology and Hepatology
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Kansas City : Site Reference ID/Investigator# 78849
A Study to Evaluate Chronic Hepatitis C Infection
Kansas City : Site Reference ID/Investigator# 78694
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Kansas City : Site Reference ID/Investigator# 86337
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
View More »
Kansas City :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Kansas City : Call for Information (Investigational Site 0007)
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034 AM4)
Kansas City : Kansas City Gastroenterology and Hepatology
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Kansas City : Call for Information (Investigational Site 0168)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Kansas City : Call for Information (Investigational Site 0175)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Kansas City :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Kansas City : Kansas City Gastroenterology and Hepatology
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Saint Louis :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Saint Louis : Updated
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
St. Louis : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
St. Louis : Site Reference ID/Investigator# 78837
A Study to Evaluate Chronic Hepatitis C Infection
St. Louis : Bruce Bacon M.D.
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
St. Louis : Washington University School Of Medicine
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
St. Louis : Call for Information (Investigational Site 0120)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
St. Louis : Washington University School Of Medicine
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Nebraska
Nevada
Las Vegas : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Las Vegas : 1241.20.00009 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
New Hampshire
Lebanon :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Lebanon :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Lebanon :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
New Jersey
Egg Harbor Township : Site Reference ID/Investigator# 78879
A Study to Evaluate Chronic Hepatitis C Infection
Egg Harbor Township :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Egg Harbour Twp :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Haddon Heights :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Hillsborough : ID Care, Inc.
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
View More »
Hillsborough : Call for Information (Investigational Site 0351)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Hillsborough : ID Care, Inc.
Gilead Sustained Virologic Response (SVR) Registry
Hillsborough : ID Care, Inc.
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Hillsborough : 1241.36.00032 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Hillsborough : Call for Information (Investigational Site 0165)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Hillsborough :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Marlton : CRI Worldwide, LLC
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Morristown : Research Center at Affiliates in Gastroenterology
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Morristown :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Morristown : Research Center at Affiliates in Gastroenterology
Gilead Sustained Virologic Response (SVR) Registry
Neptune : 1220.48.0066 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Newark : Saint Michael'S Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Township : AGA Clinical Research Associates, LLC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Vineland : The Gastroenterology Group of South Jersey
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
New Mexico
Santa Fe :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
New York
Manhasset : Biomedical Research Alliance of New York
Chronic Genotype 1 Hepatitis C virus - Adults
New York : Biomedical Research Alliance of New York
Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment
View More »
Binghamton : Binghamton Gastroenterology Associates, PC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Bingharmton : Site Reference ID/Investigator# 70137
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bronx :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Bronx : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Bronx : James J Peters Vamc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Brooklyn : 1220.48.0083 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Brooklyn :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Catskill :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Endwell : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Flushing :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Flushing : Medical Procare, Pllc
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Flushing : Office Of Sing Chan Md
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Manhasset : Site Reference ID/Investigator# 86114
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Manhasset :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Manhasset :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Manhasset : North Shore University Hospital
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Manhasset : North Shore University Hospital
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Manhasset :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Manhasset : Bristol-Myers Squibb/David E. Bernstein, Md
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Manhasset : North Shore Long Island Jewish Health System
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Monticello : Site Reference ID/Investigator# 86306
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Monticello : Upper Delaware Valley Infectious Diseases, Pc
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
New York : Mount Sinai Medical Center
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
New York : 1220.48.0012 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
New York : CliniLabs
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
New York : Weill Cornell Medical College
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
New York : Weill Cornell Medical College
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
New York : CliniLabs
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
New York :
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
New York :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
New York :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
New York : Site Reference ID/Investigator# 78882
A Study to Evaluate Chronic Hepatitis C Infection
New York :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
New York :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
New York : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
New York : Bellevue Hospital
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
New York : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
New York : New York School of Medicine
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
New York :
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
New York : Mount Sinai School of Medicine
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease
New York : Weill Cornell Medical College
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
New York : Mount Sinai School of Medicine
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
New York : Call for Information (Investigational Site 0001)
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (SCH503034-P07614 AM6)
New York : Weill Cornell Medical College
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
New York : Call for Information (Investigational Site 0139)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
New York : Call for Information (Investigational Site 0388)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
New York : Mount Sinai School Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
New York : Weill Cornell Medical College
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
New York :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
New York : New York Presbyterian Hospital: Weill Medical College of Cornell University
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Poughkeepsie : Site Reference ID/Investigator# 78744
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Poughkeepsie : Site Reference ID/Investigator# 72456
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Rochester :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Rochester :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
North Carolina
Asheville :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Asheville :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Asheville : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Asheville : Clinical Study Center of Asheville, LLC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Asheville :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
View More »
Chapel Hill :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Chapel Hill : University of North Carolina
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Chapel Hill : University Of North Carolina At Chapel Hill
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Chapel Hill : University Of North Carolina At Chapel Hill
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Charlotte : Levine Children'S Hospital At Carolinas Medical Center
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Charlotte : Call for Information (Investigational Site 0356)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Charlotte : Site Reference ID/Investigator# 78853
A Study to Evaluate Chronic Hepatitis C Infection
Charlotte :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Charlotte : Carolinas Medical Center
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Charlotte :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Charlotte : Carolinas Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Charlotte : Carolinas Medical Center
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Durham : Duke University Medical Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Durham :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Durham : Duke University Medical Center
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Durham : Duke University Medical Center
Gilead Sustained Virologic Response (SVR) Registry
Durham : Duke University Medical Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Durham : Duke University Medical Center
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Durham : Duke University Medical Center
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Fayetteville : Site Reference ID/Investigator# 78733
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Fayetteville :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Rocky Mount :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Statesville : Site Reference ID/Investigator# 78736
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Statesville : Carolinas Center for Liver Disease
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Statesville : Carolinas Center For Liver Disease
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Statesville : Carolinas Center For Liver Disease
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Wilmington : Registry Coordinating Center Updated
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Wilmington : INC Research, LLC
Ribavirin Pregnancy Registry
Winston Salem : Digestive Health Specialists, PA
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Winston-Salem : 1220.48.0021 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Winston-Salem : Site Reference ID/Investigator# 78872
A Study to Evaluate Chronic Hepatitis C Infection
Winston-Salem :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Ohio
Cincinnati : University of Cincinnati Medical Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Cincinnati : Site Reference ID/Investigator# 79113
A Study to Evaluate Chronic Hepatitis C Infection
Cincinnati :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Cincinnati : Site Reference ID/Investigator# 86314
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Cincinnati : University of Cincinnati
Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
View More »
Cincinnati : University of Cincinnati Medical Center
Gilead Sustained Virologic Response (SVR) Registry
Cincinnati : University of CIncinnati / Holmes Building
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Cleveland : University Hospitals Case Medical Center
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Cleveland : University Hospitals Case Medical Center
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Cleveland : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Cleveland : Call for Information (Investigational Site 0162)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Oklahoma
Oklahoma City :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Tulsa : Options Health Research LLC
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Tulsa : Options Health Research LLC
Gilead Sustained Virologic Response (SVR) Registry
Tulsa : 1241.20.00024 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Tulsa : Healthcare Research Consultants
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
View More »
Tulsa : Options Health Research, Llc
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Tulsa : Call for Information (Investigational Site 0138)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Tulsa : Options Health Research, Llc
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Tulsa : Options Health Research, Llc
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Tulsa : Options Health Research, Llc
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Oregon
Bend :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Portland : 1220.48.0058 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Portland : Oregon Health Science University
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Portland : 1241.20.00013 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Portland : Call for Information (Investigational Site 0343)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Pennsylvania
Dubois :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Jenkintown : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Philadelphia : Children'S Hospital Of Philadelphia
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Philadelphia : CRI Worldwide, LLC
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Philadelphia : Site Reference ID/Investigator# 78869
A Study to Evaluate Chronic Hepatitis C Infection
View More »
Philadelphia : Site Reference ID/Investigator# 70148
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Philadelphia : Site Reference ID/Investigator# 70136
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Philadelphia :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Philadelphia : Drexel University College of Medicine
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Philadelphia :
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Philadelphia : Hospital of the University of Pennsylvania
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Philadelphia : Thomas Jefferson University
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Philadelphia : University Of Pennsylvania
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Philadelphia : CRI Worldwide, LLC
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Philadelphia : University Of Pennsylvania
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Pittsburgh :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Pittsburgh : University of Pittsburgh
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Rydal : Call for Information (Investigational Site 0182)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Rhode Island
Providence : Rhode Island Hospital
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Providence :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Providence : University Gastroenterology
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Tennessee
Germantown : Gastroenterology Center of the MidSouth, P.C.
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Germantown : Tennessee
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
Germantown : Site Reference ID/Investigator# 86133
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Germantown :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Germantown : Gastroenterology Center of the MidSouth, P.C.
Gilead Sustained Virologic Response (SVR) Registry
View More »
Germantown : Gastro One
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Germantown : Gastro One
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Germantown :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Germantown : Gastro One
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Knoxville : New Orleans Center for Clinical Research-Knoxville
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Memphis :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Nashville : Nashville Gastrointestinal Specialists, Inc
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Nashville : The Frist Clinic
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Nashville :
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
Nashville :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Nashville : Dr. Robert Herring Jr
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Nashville : Nashville Gastrointestinal Specialists, Inc
Gilead Sustained Virologic Response (SVR) Registry
Nashville : The Frist Clinic
Gilead Sustained Virologic Response (SVR) Registry
Nashville : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Nashville : Nashville Medical Research Institute
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Nashville :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Nashville : Nashville Medical Research Institute
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Texas
Arlington : The North Texas Research Institute
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Arlington : 1220.48.0063 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Arlington : Call for Information (Investigational Site 0367)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Arlington :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Arlington :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
View More »
Arlington : The North Texas Research Institute
Gilead Sustained Virologic Response (SVR) Registry
Arlington : Texas Clinical Research Institute, LLC
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Arlington : 1241.36.00002 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Arlington :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Arlington : 1241.21.0012 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Austin : 1220.48.0029 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Austin :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Austin : 1241.20.00005 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Austin : 1241.21.0005 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Dallas : 1220.48.0056 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Dallas : 1220.48.0017 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Dallas : 1220.48.0071 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Dallas : Call for Information (Investigational Site 0126)
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Dallas :
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Dallas :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Dallas :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Dallas : 1241.20.00017 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Dallas : Annette C. and Harold C. Simmons Transplant Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Dallas : Call for Information (Investigational Site 0158)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Dallas : Call for Information (Investigational Site 0153)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Dallas : Ut Southwestern Medical Center
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Dallas : 1241.21.0007 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Fort Worth : Call for Information (Investigational Site 0417)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Forth Worth : 1220.48.0081 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Galveston :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Houston : Kelsey Research Foundation
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Houston : Research Specialists of Texas
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Houston : Baylor College of Medicine - St. Luke's Episcopal Hospital
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Houston : Texas Children'S Hospital
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Houston : 1220.48.0009 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Houston : 1220.48.0068 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Houston : Baylor College of Medicine
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Houston : Baylor College of Medicine
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Houston : Call for Information (Investigational Site 0134)
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Houston : Call for Information (Investigational Site 0362)
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Houston : Site Reference ID/Investigator# 78759
A Study to Evaluate Chronic Hepatitis C Infection
Houston : Site Reference ID/Investigator# 78679
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Houston :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Houston : Site Reference ID/Investigator# 70142
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Houston :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Houston : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Houston : Texas Children's Hospital
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Houston : Kelsey Research Foundation
Gilead Sustained Virologic Response (SVR) Registry
Houston : Research Specialists of Texas
Gilead Sustained Virologic Response (SVR) Registry
Houston : 1241.20.00012 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Houston : Research Specialists of Texas
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Houston : Baylor College Of Medicine
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Houston : Vamc
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Houston : Call for Information (Investigational Site 0128)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Houston : Call for Information (Investigational Site 0133)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Houston : Call for Information (Investigational Site 0140)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Houston :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Houston : Baylor College Of Medicine
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Houston : St. Luke'S Episcopal Hospital - Baylor College Of Medicine
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Houston : 1241.21.0010 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Houston : Baylor College Of Medicine
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Houston : Liver Associates Of Texas
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Houston : Liver Associates Of Texas
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Houston : St. Luke'S Episcopal Hospital - Baylor College Of Medicine
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Houston : University Of Texas Health Science Center At Houston
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Houston : Va Medical Center (151)
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
San Antonio : Alamo Medical Research, Ltd.
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
San Antonio : 1220.48.0016 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
San Antonio :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
San Antonio :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
San Antonio : Site Reference ID/Investigator# 78757
A Study to Evaluate Chronic Hepatitis C Infection
San Antonio : Site Reference ID/Investigator# 78722
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
San Antonio :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
San Antonio : Site Reference ID/Investigator# 84481
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
San Antonio : Site Reference ID/Investigator# 70146
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
San Antonio : Dr. Eric Lawitz
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
San Antonio : Alamo Medical Research, Ltd.
Gilead Sustained Virologic Response (SVR) Registry
San Antonio : Alamo Medical Research
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
San Antonio : Alamo Medical Research
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
San Antonio :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
San Antonio :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects
San Antonio : Alamo Medical Research
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Antonio : Alamo Medical Research
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
San Antonio : Alamo Medical Research
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
San Antonio : Alamo Medical Research
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
San Antonio : Alamo Medical Research
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
San Antonio : Alamo Medical Research
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
San Antonio : Alamo Medical Research
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Utah
Murray : Site Reference ID/Investigator# 86115
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
Murray : 1241.36.00008 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Salt Lake City : Lifetree Clinical Research
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Salt Lake City : University of Utah
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Salt Lake City : University of Utah
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
View More »
Salt Lake City : Lifetree Clinical Research
Gilead Sustained Virologic Response (SVR) Registry
Salt Lake City : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Salt Lake City : Call for Information (Investigational Site 0143)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Vermont
Burlington :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Virginia
Alexandria : Call for Information (Investigational Site 0128)
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Charlottesville :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Fairfax : Metropolitan Research
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Fairfax : Inova Fairfax Hospital For Children
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Fairfax : Site Reference ID/Investigator# 78878
A Study to Evaluate Chronic Hepatitis C Infection
View More »
Fairfax :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Fairfax : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Fairfax : Vinod Rustgi, MD
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Fairfax : Metropolitan Liver Diseases Center
Gilead Sustained Virologic Response (SVR) Registry
Fairfax : Metropolitan Research
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Fairfax : Metropolitan Research
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Fairfax :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Fairfax : Metropolitan Research
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Fairfax : Metropolitan Research
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Fairfax : Metropolitan Research
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Fairfax : Metropolitan Research
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Fairfax : Metropolitan Research
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Falls Church : Inova Fairfax Hospital
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Newport News : Site Reference ID/Investigator# 78881
A Study to Evaluate Chronic Hepatitis C Infection
Newport News : Site Reference ID/Investigator# 84487
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Newport News : Bon Secours Saint Mary's Hospital of Richmond
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Norfolk : Digestive and Liver Disease Specialists
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Norfolk : Call for Information (Investigational Site 0133)
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Norfolk :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Norfolk :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Norfolk : Site Reference ID/Investigator# 84485
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Norfolk : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
Norfolk : Michael Ryan, MD
Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects
Norfolk : Digestive and Liver Disease Specialists
Gilead Sustained Virologic Response (SVR) Registry
Norfolk : Digestive and Liver Disease Specialists
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Norfolk : Call for Information (Investigational Site 0177)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Norfolk :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Richmond : Liver Institute of Virginia, Bon Secours Health System
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Richmond : 1220.48.0026 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Richmond : Liver Institute of Virginia, Bon Secours Health System
Gilead Sustained Virologic Response (SVR) Registry
Richmond : Call for Information (Investigational Site 0156)
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Richmond :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Richmond : Virginia Commonwealth University
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Washington
Seattle : 1220.48.0092 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seattle :
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Seattle : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Seattle :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Seattle : Site Reference ID/Investigator# 78861
A Study to Evaluate Chronic Hepatitis C Infection
View More »
Seattle : Site Reference ID/Investigator# 78719
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Seattle : Virginia Mason Medical Center
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Seattle : Virginia Mason Medical Center
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Seattle : Virginia Mason Medical Center
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Tacoma : Charles River Clinical Services Northwest, Inc.
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Wenatchee : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Wisconsin
Madison :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Madison : Site Reference ID/Investigator# 86341
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Madison : Dean Clinic
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Madison : Dean Clinic
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Madison : Dean Clinic
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Argentina
Buenos Aires : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Buenos Aires : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Buenos Aires : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Buenos Aires : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
View More »
Bunos Aires : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Ciudad De Buenos Aires : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Ciudad De Buenos Aires : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Ciudad De Buenos Aires : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Ciudad De Buenos Aires : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Ciudad De Buenos Aires : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Cordoba : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Mar Del Plata : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Prov De Santa Fe : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Prov De Santa Fe : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Prov De Santa Fe : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Prov De Santa Fe : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Prov. Buenos Aires : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Prov. Buenos Aires : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Australia
Adelaide : Royal Adelaide Hospital
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Adelaide : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Adelaide : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Adelaide : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Adelaide : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
View More »
Adelaide : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Box Hill : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Camperdown : 1241.36.61005 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Camperdown : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Clayton : Monash University, Department of Medicine
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Clayton : Monash University, Dept. of Medicine
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Clayton : 1241.36.61004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Clayton : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Clayton : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Clayton Vic : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Clayton Vic : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Clayton Vic : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Concord :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Darlinghurst : 1241.36.61001 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Darlinghurst : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Darlinghurst : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Darlinghurst : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Darlinghurst : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Darlinghurst Nsw : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Fitzroy :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Fitzroy : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Fitzroy : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Fitzroy : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Fremantle : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Fremantle : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Fremantle : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Greenslopes : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Greenslopes : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Heidelberg : 1241.36.61008 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Heidelberg : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Heidelberg : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Heidelberg : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Heidelberg Vic : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Herston : Royal Brisbane and Women's Hospital
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Herston : Royal Brisbane and Women's Hospital
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Herston :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Herston : Updated
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
Herston : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Herston : 1241.36.61002 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Herston : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Herston : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Kogarah : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Kogarah : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Melborne : Monash Medical Centre
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Melbourne : Alfred Hospital
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Melbourne : Austin Health
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Melbourne : Alfred Hospital
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Melbourne :
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Melbourne : Alfred Hospital, Department of Gastroenterology
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Melbourne : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Melbourne :
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Melbourne :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Melbourne : The Alfred Hospital
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Melbourne :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Melbourne : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Melbourne : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Melbourne : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Nedlands : Linear Clinical Research Ltd
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Nedlands : Royal Perth Hospital
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Nedlands : Royal Perth Hospital
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Nedlands : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Newcastle : Hunter Pharmacotherapy
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
North Adelaide : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Parville : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Parville : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Perth : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Perth : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Perth : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Prahan : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Prahran : 1241.36.61006 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Prahran : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Randwick : 1241.36.61007 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Randwick : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Randwick : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
South Granville : Merck Sharp & Dohme/Australia
A Study of Different Durations of Treatment With MK-5172 in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039 AM1)
South Granville : Merck Sharp & Dohme/Australia
A Study of the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Participants With Chronic Hepatitis B (P08450 AM1)
South Granville : Merck Sharp & Dohme/Australia
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
South Granville : Merck Sharp & Dohme/Australia
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172 (MK-5172-013 AM3)
St Albans : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Sydney : St Vincent's Hospital
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Sydney : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Sydney :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Wentworthville :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Westmead Nsw : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Westmead Nsw : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Woolloongabba : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Woolloongabba N/A :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Austria
Gratwein :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
Graz :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
Graz : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Graz : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Innsbruck :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
View More »
Innsbruck :
Telaprevir Open-Label Study in Co-Infected Patients
Klagenfurt :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
Linz : 1220.48.4303 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Linz :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Linz :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
Linz : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Salzburg : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Vienna : Merck, Sharp & Dohme Ges.m.b.H.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Wien : 1220.48.4302 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Wien : 1220.48.4301 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Wien : 1220.48.4304 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Wien : Updated
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
Wien :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Wien :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy (PEGHOPE)
Wien :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Wien : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Wien : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Wien :
Telaprevir Open-Label Study in Co-Infected Patients
Wien : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Belgium
Antwerp : ZNA Stuivenberg / MSOC Free Clinic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Antwerpen :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Antwerpen :
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected Patients
Antwerpen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Antwerpen : 1241.36.32006 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
View More »
Antwerpen : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Antwerpen :
Telaprevir Open-Label Study in Co-Infected Patients
Bouge : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Brussel :
Telaprevir Open-Label Study in Co-Infected Patients
Brussels : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Brussels :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Brussels :
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected Patients
Brussels :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Brussels : Updated
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Brussels : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bruxelles : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Bruxelles : 1220.48.3201 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bruxelles : 1220.48.3207 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bruxelles : MSD Belgium BVBA/SPRL
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002 AM1)
Bruxelles : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bruxelles : 1241.36.32001 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Bruxelles : MSD Belgium BVBA/SPRL
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Bruxelles : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bruxelles :
Telaprevir Open-Label Study in Co-Infected Patients
Charleroi :
Telaprevir Open-Label Study in Co-Infected Patients
Edegem : 1220.48.3204 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Edegem : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Edegem : 1241.36.32004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Gent : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Gent :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Gent :
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected Patients
Gent :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Gent : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Gent : 1241.36.32005 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Gent :
Telaprevir Open-Label Study in Co-Infected Patients
Gilly : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Hasselt : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Heusy : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Leuven : 1220.48.3202 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Leuven :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Leuven : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Leuven : 1241.36.32002 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Leuven :
Telaprevir Open-Label Study in Co-Infected Patients
Liege :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Liege : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Liege : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Liège : 1220.48.3203 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Liège : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Liège : 1241.36.32003 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Liège :
Telaprevir Open-Label Study in Co-Infected Patients
Mons : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Montignies Sur Sambre : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Namur : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Oostende : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Roeselare : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Verviers : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Brazil
Botucatu :
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
Campinas :
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
Porto Alegre : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Rio De Janeiro : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Santo Andre :
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
View More »
Sao Paulo :
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
Sao Paulo : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Sorocaba :
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
Bulgaria
Pleven :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Pleven :
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Plodiv : University Multiprofile Hospital for Active Treatment "Sveti Georgi"
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Plovdiv :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Plovdiv :
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
View More »
Sofia :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Sofia :
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Sofia : Multiprofile Hospital for Active Treatment "Tokuda Hospital"
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Sofia : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Stara Zagora :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Stara Zagora :
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Varna :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
Varna :
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Varna : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Canada
Calgary : 1220.48.1011 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Calgary : University of Calgary, Heritage Medical Research Center
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Calgary : University of Calgary, Heritage Medical Research Center
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Calgary : University of Calgary
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Calgary : 1241.36.01005 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
View More »
Edmonton : 1220.48.1012 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Edmonton : University of Alberta Hospital
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Edmonton : University of Alberta Hospital
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Edmonton : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Edmonton : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Edmonton : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Hamilton : 1220.48.1013 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Hamilton : 1241.20.01006 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Kirkland : Merck Frosst Canada Ltd.
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Kirkland : Merck Frosst Canada Ltd.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Laval : Algorithme Pharma, Inc.
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
London : 1241.27.0100 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
London : 1241.36.01003 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Montreal : CHUM - Centre Hospitalier de l'Universite de Montreal
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Montreal : Algorithme Pharma
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Montreal : Algorithme Pharma, Inc.
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Montreal :
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Montreal : 1241.27.0500 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Montreal :
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Montreal : 1241.20.01007 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Montreal : Centre Hospitalier de l'Universite de Montreal (CHUM)
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Montreal : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Montreal : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Montreal : Montreal Chest Institute
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Montreal : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Montreal : Immunodeficiency Service Montreal Chest Institute McGill University Health Centre
Trial of Citalopram for the Prevention of Depression
Montréal : Centre hospitalier de l'Université de Montréal
Ribavirin Dose Optimization for the Treatment of Hepatitis C
Ottawa : The Ottawa Hospital, General Campus
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Ottawa : 1220.48.1004 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Ottawa : 1241.27.0300 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Ottawa : 1241.36.01001 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Ottawa : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Quebec : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Quebec : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Quebec City : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Regina : University of Regina
Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity
Saskatoon : University of Saskatchewan
Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity
St. Romuald : Pro-recherche
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Ste-Foy : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Sudbury : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Toronto : East Toronto Hepatitis C Program
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Toronto : Toronto General Hospital
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Toronto : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Toronto : 1220.48.1006 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Toronto : 1220.48.1005 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Toronto : 1220.48.1015 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Toronto : Biovail Contract Research
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
Toronto : 1241.20.01002 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Toronto : 1241.36.01007 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Toronto : 1241.36.01004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Toronto : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Toronto : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Toronto : University Health Network - Toronto General Hospital Division
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Toronto : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Toronto : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Truro : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Vancouver : Vancouver ID Research and Care Centre Society
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Vancouver : Liver and Intestinal Research Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Vancouver : Downtown Infectious Diseases Clinic (University of British Columbia)
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Vancouver : 1220.48.1001 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Vancouver : 1220.48.1016 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Vancouver : 1220.48.1003 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Vancouver :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Vancouver : Liver and Intestinal Research Centre
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
Vancouver :
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Vancouver : 1241.27.0200 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Vancouver : 1241.27.0700 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Vancouver : 1241.27.0600 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Vancouver : Liver and Intestinal Research Center
Gilead Sustained Virologic Response (SVR) Registry
Vancouver : 1241.20.01001 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Vancouver : 1241.20.01008 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Vancouver : 1241.20.01010 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Vancouver : Gastrointestinal Research Institute (GIRI)
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Vancouver : 1241.36.01006 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Vancouver : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Vancouver : Providence Health Care- St. Paul's Hospital
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Vancouver : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Vancouver : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Vancouver : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Vaughan : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Vaughan : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Victoria : 1220.48.1007 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Victoria : 1241.27.0400 Boehringer Ingelheim Investigational Site
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
Victoria : 1241.20.01003 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Victoria : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Victoria : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Victoria : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Victoria : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Victoria : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Whitby : 1241.20.01005 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Winnipeg : University of Manitoba, Health Sciences Center
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Winnipeg : 1220.48.1009 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Winnipeg : University of Manitoba, Health Sciences Center
Gilead Sustained Virologic Response (SVR) Registry
Winnipeg : 1241.36.01002 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Winnipeg : The University of Manitoba
Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity
Chile
Santiago : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Santiago : Merck Sharp & Dohme (I.A.) Corp.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
China
Beijing : Wei Lai
A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.
Beijing : 302 military hospital of China
A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection
Beijing : National institues for Food and Drug control
A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection
Beijing :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Beijing : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
View More »
Beijing : Local Institution
Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China
Beijing : Beijing Ditan Hospita
EFFORT Extension Study
Beijing : Beijing Friendship Hospital Attached To The Capital Medical University
EFFORT Extension Study
Beijing : Department of Infectious Disease, First Hospital of Peking University
EFFORT Extension Study
Beijing : 302 Military Hospital Of China
EFFORT Extension Study
Beijing : BeiJing YouAn Hospital ,Capital Medical University
EFFORT Extension Study
Beijing : People's Hospital Under Beijnig University
EFFORT Extension Study
Chang Chun : Hepatobiliary Disease Hospital of Jilin Province
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Changchun :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Changchun : First Hospital .Jilin Unniversity
EFFORT Extension Study
Changsha :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Changsha : Xiangya Hospital Central-South Univrsity
EFFORT Extension Study
Changshu : Local Institution
Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China
Chengdu : West China Hospital.SiChuan University
EFFORT Extension Study
Chongqing : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Chongqing : The Second Affiliated of ChongQing University of Medical Science
EFFORT Extension Study
Chongqing : Southwest Hospital
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Daqing : Local Institution
Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China
Foshan : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Guangzhou :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Guangzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Guangzhou : No. 8 People's Hospital In GuangZhou
EFFORT Extension Study
Guangzhou : The Third Hospital of Sun Yat-Sen University
EFFORT Extension Study
Guangzhou : Department of Infectious Disease, Nanfang Hospital
EFFORT Extension Study
Hangzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Hangzhou : The First Affiliated Hospital of College of Medicine, Zhejiang University
EFFORT Extension Study
Hangzhou : The Sixth People's Hospital of Hangzhou
EFFORT Extension Study
Harbin : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Hong Kong : Department of Medicine, Queen Mary Hospital
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
Jinan :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Jinan : JiNan Infectious Diseases Hospital
EFFORT Extension Study
Lanzhou :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Liuzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Nan Jing : The Second Affiliated Hospital of the Southeast University
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Nanchang : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Nanjing :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Nanjing : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Nanjing : No.81 Hospital of PLA
EFFORT Extension Study
Nanning : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Nanyang : Nanyang Central Hospital
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Ordos : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Shang hai : Ruijin hospital Shanghai Jiaotong University school of medicine
A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection
Shanghai : Fudan University Zhongshan Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Shanghai : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Shanghai : Changhai Hospital affiliated to Second Military Medical University
EFFORT Extension Study
Shanghai : Huashan Hospital，Fudan University
EFFORT Extension Study
Shanghai : Shanghai Ruijin Hospital
EFFORT Extension Study
Shanghai : No.85 Hospital of PLA
EFFORT Extension Study
Shengyang : ShengJing Hospital of China Medical University
EFFORT Extension Study
Shenyang :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Shenzhen : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Shijiazhuang : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Shijiazhuang : The Fifth Hospital of Shijiazhuang
Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus
Suzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Tianjin :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Tianjin : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Urumqi : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Wenzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Wuhan : Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
EFFORT Extension Study
Wuxi : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Xiamen : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Xian : Tangdu Hospital
EFFORT Extension Study
Yangzhou : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Zhaoqing : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Zhengzhou :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Zhenjiang : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
Colombia
Bogota : MDS Colombia SAS
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Czech Republic
Most :
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
Praha : Merck Sharp and Dohme s.r.o.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Denmark
Glostrup : Merck Sharp & Dohme
A Study of the Combination Regimen MK-5172, MK-8742, and Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Hvidovre : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Egypt
Alexandria : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Cairo : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Cairo : MSD Scientific Office
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059 AM1)
Cairo : Kasr Alaini school of medicne
Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Giza : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
View More »
Shebin El-Kom : National Liver Institute
Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C
Tanta : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Estonia
Kohtla-järve : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Kohtla-järve : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pärnu : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Pärnu : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tallin : West Tallinn Central Hospital
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
View More »
Tallinn : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Tallinn : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tartu : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Tartu : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tartu : Tartu University Hospital
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Finland
Hus : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
France
Aix en Provence : Service d'Hépatogastroentérologie et d'endoscopie digestive - CH du Pays d'Aix
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Amiens : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Amiens : Service d'Hépatogastroentérologie - Hôpital Nord
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Angers : Service d'Hépatologie - Gastroentérologie - Cancérologie digestive - CHU Angers
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Argenteuil : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
View More »
Argenteuil : Service d'Hépatogastroentérologie - CH Victor Dupouy
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Besançon : Service d'Hépatogastroentérologie - Hôpital Jean Minjoz
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Bobigny : Service d'Hépatogastroentérologie - Hôpital Avicenne
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Bondy : Service d' Hépatogastroentérologie - Hôpital Jean Verdier
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Boulogne-billancourt : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bourgoin Jallieu : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bourgoin-Jallieu : Cabinet Médical
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Brest : Service d'Hépatogastroentérologie - Hôpital de la Cavale Blanche
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Caen : Service d'Hépatologie - Gastroentérologie - Nutrition -Hôpital de la Côte de Nacre
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Chambray Les Tours : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Chateauroux : Service d'Hépatogastroentérologie - CH de Chateauroux
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Clermont-Ferrand : 1220.48.3314 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Clermont-Ferrand : Service d'Hépatogastroentérologie - Hotel Dieu
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Clichy :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Clichy : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Clichy : Hôpital Beaujon
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Clichy : Service d'Hépatogastroentérologie - Hôpital Beaujon
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Clichy : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Clichy : 1241.21.33005 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Clichy Cedex : 1220.48.3301 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Clichy Cedex : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Clichy Cedex : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Clichy Cedex : Local Institution
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Corbeil-Essonnes : Service d'Hépatogastroentérologie - CH Sud Francilien
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret Updated
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518 AM2)
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Creil : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Creteil : Site Reference ID/Investigator# 72834
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Creteil : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Creteil : 1241.36.33004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Creteil : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Creteil : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Creteil : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Creteil Cedex : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Dijon : Service d'Hépatogastroentérologie - Hôpital du Bocage
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Epinay-sur-seine : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Freyming-merlebach : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Gonesse : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Grasse : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Grenoble : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Grenoble Cedex 9 : CHU de Grenoble
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Grenoble cédex 9 : 1241.21.33007 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
La Roche sur Yon : Service d'Hépatogastroentérologie - CH La Roche sur Yon
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Le Kremlin-Bicetre : Service des Maladies du Foie et de l'appareil Digestif - Hôpital de Bicêtre
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Le Mans : Département d'Hépatogastroentérologie - CH Le Mans
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Lille : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lille : Service d'Hépatogastroentérologie - CHRU - Hôpital Claude Huriez
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Lille : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Lille Cedex : 1220.48.3311 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Limoges : Unité de Médecine Interne A - Hôpital Dupuytren
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Lomme : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lyon :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Lyon : Hôpital Croix-Rousse
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Lyon : Service d'Hépatogastroentérologie - Hotel Dieu
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Lyon : 1241.21.33003 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Lyon Cedex 02 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Lyon Cedex 04 : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Mantes La Jolie : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Marseille :
A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Marseille :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Marseille :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Marseille : Service d'Hépatogastroentérologie - Hôpital Saint Joseph
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Marseille : 1241.21.33001 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Marseille Cedex 08 : 1220.48.3303 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Marseille Cedex 08 : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Marseille Cedex 08 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Marseille Cedex 09 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Meaux : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Montauban : Service d'Hépatogastroentérologie - CH Montauban
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Montelimar : Service d'Hépatogastroentérologie - CH Montélimar
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Montpellier :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Montpellier : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Montpellier : Service d'Hépatogastroentérologie - Hôpital Saint Eloi
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Montpellier : 1241.21.33002 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Montpellier Cedex 5 : Hôpital Saint-Eloi
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Montpellier Cedex 5 : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Montpellier Cedex 5 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Montpellier Cedex 5 : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Montpellier Cedex 5 : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Montpellier Cedex 5 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Nantes : Service d'Hépatogastroentérologie - Hôpital Nord Laennec
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Nice :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Nice Cedex 03 : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Nice Cedex 03 : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Nice Cedex 03 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Nice Cedex 03 N/A :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Nice Cedex 3 : 1220.48.3305 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Nice N/A :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Orleans : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Orléans : Service d'Hépatogastroentérologie - Hôpital de la Source
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Paris : 1220.48.3302 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Paris : Site Reference ID/Investigator# 71418
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Paris : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Paris : Service d'Hépatogastroentérologie - Hôpital Cochin
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Paris : Service d'Hépatogastroentérologie - Hôpital La Pitié Salpétrière
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Paris : Service d'Hépatogastroentérologie - Hôpital Necker
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Paris : Service d'Hépatogastroentérologie - Hôpital Tenon
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Paris : 1241.36.33008 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Paris : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Paris : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris : 1241.21.33004 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Paris : 1241.21.33008 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Paris : Hopital Cochin CIC de vaccinologie
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
Paris Cedex 10 : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Paris Cedex 12 :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Paris Cedex 12 : Hôpital Saint Antoine
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Paris Cedex 12 : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Paris Cedex 12 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Paris Cedex 12 : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Paris Cedex 13 : Hôpital La Pitié Salpétrière
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Paris Cedex 13 : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Paris Cedex 13 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Paris Cedex 14 : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Paris Cedex 20 : 1220.48.3309 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
PAU : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pessac : Site Reference ID/Investigator# 71417
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Pessac : Service d'Hépatogastroentérologie et d'Assistance nutritive - Hôpital Haut-Lévêque
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Pessac Cedex : 1220.48.3316 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Pessac Cedex : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Reims : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Rennes : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Rennes : Service d'Hépatogastroentérologie - Hôpital Pontchaillou
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Rennes Cedex 09 : 1220.48.3315 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Rennes Cedex N/A :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Rouen : Service d'Hépatogastroentérologie - CHU Rouen
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Saint Dizier : Service d'Hépatogastroentérologie - CH Saint Dizier
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Saint Laurent du Var : 1220.48.3312 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Saint Laurent du Var Cedex : 1241.36.33006 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Saint Nazaire : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Strasbourg : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Strasbourg : Service d'Hépatogastroentérologie, Clinique médicale B - Hôpital Civil
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Toulouse : Service d'Hépatogastroentérologie - Hôpital Purpan
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Toulouse : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Toulouse : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Toulouse Cedex 09 : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Tours : Service d'Hépatogastroentérologie - Hôpital Trousseau
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Vandoeuvre Cedex : 1241.21.33006 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Vandoeuvre Cedex : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Vandoeuvre les Nancy : Service d'Hépatogastroentérologie - Hôpital Brabois
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Vandoeuvre Les Nancy : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Vannes : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Villejuif : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Villejuif : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Villejuif Cedex :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Villejuif Cedex : Centre Hépatobiliaire Paul Brousse
Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
Villeneuve Maguelone : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Villeneuve St Georges : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Georgia
Tbilisi :
An Observational Study of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C
Germany
Aachen : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Aachen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Berlin : 1220.48.4902 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Berlin : 1220.48.4904 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Berlin :
A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
View More »
Berlin :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Berlin : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Berlin : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Berlin : 1241.20.49004 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Berlin : 1241.20.49002 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Berlin : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Berlin : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Berlin : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Berlin : Charite CVK
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Berlin : Leberzentrum am Checkpoint
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Berlin : Private Practice
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Berlin :
Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
Berlin : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Berlin :
Telaprevir Open-Label Study in Co-Infected Patients
Bonn : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Bonn : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Bonn : Universitaetsklinikum Bonn
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Bonn : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Bonn :
Telaprevir Open-Label Study in Co-Infected Patients
Burghausen : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Burghausen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Dortmund : 1220.48.4913 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Dortmund :
Telaprevir Open-Label Study in Co-Infected Patients
Duesseldorf : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Duesseldorf : Zentrum für HIV und Hepatitis
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Dusseldorf : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Düsseldorf : 1220.48.4906 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Düsseldorf : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Düsseldorf : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Erlangen : 1220.48.4912 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Erlangen : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Erlangen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Essen : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Essen :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Essen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Essen : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Essen : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Essen : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Essen : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Frankfurt : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Frankfurt : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Frankfurt : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Frankfurt : J.W. Goethe Universitaetsklinikum
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Frankfurt : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Frankfurt :
Telaprevir Open-Label Study in Co-Infected Patients
Frankfurt : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Frankfurt A. M. :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Frankfurt A. M. :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Frankfurt am Main : 1220.48.4901 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Frankfurt am Main : 1241.20.49001 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Frankfurt Am Main : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Frankfurt An Der Oder : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Frankfurt Main : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Freiburg : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Haar : MSD Sharp & Dohme GMBH
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002 AM1)
Haar : MSD Sharp & Dohme GMBH Updated
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518 AM2)
Haar : MSD Sharp & Dohme GMBH
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (SCH503034-P07614 AM6)
Haar : MSD Sharp & Dohme GMBH
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Haar : MSD Sharp & Dohme GMBH
Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males (MK-8742-002 AM1)
Halle : Martin-Luther University Halle-Wittenberg
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
Hamburg : 1220.48.4908 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Hamburg :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Hamburg :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Hamburg : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Hamburg : Asklepios Klinik Sankt Georg H
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Hamburg : Universitatsklinikum
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Hamburg : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Hamburg : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Hamburg : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Hamburg : Universitaetsklinikum Hamburg Eppendorf
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Hamburg : ifi Studien und Projekte GmbH
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Hamburg : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Hamburg : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Hamburg : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Hamburg : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Hamburg : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Hannover : Updated
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
Hannover :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Hannover : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Hannover : Medizinische Hochschule Hannov
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Hannover : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Hannover : Medizinische Hochschule Hannover
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Hannover :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Hannover : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Hannover :
Telaprevir Open-Label Study in Co-Infected Patients
Hannover : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Heidelberg :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Heidelberg : Medizinische Klinik IV, Dep. o
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Heidelberg : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Heidelberg : Universitaetsklinik Heidelberg
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Heidelberg : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Heidelberg : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Heidelberg : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Herne : 1220.48.4907 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Herne :
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
Herne : Gastroenterologische Gemeinsch
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Herne : 1241.20.49009 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Herne : Gastroenterologische Gemeinschaftspraxis
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Herne : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Kassel : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Kassel : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Kiel : 1220.48.4914 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Kiel :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Kiel : 1241.20.49008 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Kiel : Gastroenterologische Gemeinschaftspraxis
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Kiel : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Köln :
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
Köln : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Köln : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Köln :
Telaprevir Open-Label Study in Co-Infected Patients
Leipzig : 1220.48.4903 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Leipzig :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Leipzig :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
Leipzig : 1241.21.49004 Boehringer Ingelheim Investigational Site
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Leipzig : Universitaetsklinikum Leipzig
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Leipzig : Novartis Investigative Site
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
Leverkusen : Gemeinschaftspraxis Gastroenterologie
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Lübeck : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Lübeck : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Magdeburg : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Magdeburg : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Magdeburg : 1241.20.49006 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Mainz : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Mainz : 1220.48.4911 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Mainz : Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik
Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen
Mainz : Universitaetsklinikum Mainz
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Mainz : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Mannheim : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Mannheim : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Muenchen : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Muenchen : Klinikum der LMU Grosshadern
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Muenster : Centrum interdisziplinaere Medizin
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Munchen : Klinikum der Universität Münch
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
München : 1241.20.49003 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
München :
Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
Münster :
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Münster : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Oberhausen : 1241.20.49010 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Rottenburg : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Rottenburg : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Starnberg : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Stuttgart :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Stuttgart :
Telaprevir Open-Label Study in Co-Infected Patients
Tübingen : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Tübingen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tübingen : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Tübingen :
Telaprevir Open-Label Study in Co-Infected Patients
Tuebingen : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Tuebingen : Universitaetsklinik Tuebingen
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Ulm : 1220.48.4915 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Ulm : 1241.20.49005 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Ulm : Universitaetsklinikum Ulm
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
Ulm : Updated
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Wuppertal : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Würzburg :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Greece
Alexandroupolis : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Athens : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Athens : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Athens : 1241.36.30001 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Ioannina : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
View More »
Ioannina : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Larissa : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Larissa : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Nea Kifissia : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Nea Kifissia : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Patra : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Patra : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Rhodes : 1241.36.30004 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Thesaloniki : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Thessaloniki : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Thessaloniki : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Guatemala
Guatemala : MSD CARD
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Hong Kong
Hong Kong : Merck Sharp & Dohme (Asia) Ltd.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Kowloon : Princess Margaret Hospital
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
New Territories : Tuen Mun Hospital
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Pokfulam : Queen Mary Hospital
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Shatin : Prince of Wales Hospital
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
View More »
Tai Po : Alice Ho Miu Ling Nethersole Hospital
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Hungary
Ajka : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Balassagyarmat : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bekescsaba : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Budapest : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Budapest : Szt. László Hospital
Continuing Treatment With Pegasys and Copegus
View More »
Budapest :
Telaprevir Open-Label Study in Co-Infected Patients
Debrecen : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Gyula : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Kaposvar : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Kecskemet : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Miskolc : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Nyíregyháza : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pecs : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Sopron : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Szekesfehervar : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Székesfehérvár : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Szolnok : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Szombathely : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tatabánya : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Zalaegerszeg : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
India
Chandigarh : School of Public Health, Post Graduate Institute of Medical Education and Research
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine
Gurgaon : MSD Pharmaceuticals Pvt. Ltd
Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063 AM2)
Guwahati : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Hyderabad : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Vijaywada : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Ireland
Dublin : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Dublin : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Dublin : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Dublin 3 : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Israel
Afula :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Ashdod :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Ashkelon :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Ashkelon :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Bat Yam :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
View More »
Bat Yam :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Beer Sheva :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Beer Sheva :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Beer Sheva :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Beer-Sheva : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Haifa :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Haifa :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Haifa : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Haifa :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Hod Hasharon : Merck Sharp & Dohme Co. Ltd.
A Study of Different Durations of Treatment With MK-5172 in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039 AM1)
Hod Hasharon : Merck Sharp & Dohme Co. Ltd.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Holon :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Holon :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Holon :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Jerusalem :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Jerusalem :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Jerusalem : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Kfar Saba :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Kfar Saba :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Nahariya :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Nahariya :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Nahariya :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Nazareth :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Petach Tikva : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Petach Tikva :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Petach Tikva :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Petach Tikva :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Petah Tiqwa :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Ramat Gan :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Ramat Gan :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Rehovot :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Rehovot :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Rishon Lezion :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Safed :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Safed :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Safed :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Tel Aviv :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Tel Aviv :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Tel Aviv :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Tiberias :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Tiberias :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Zefat : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Zefat : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Zerifin :
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Zerifin :
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Zerifin :
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Italy
Antella (fi) : 1241.36.39025 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Arezzo : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Arezzo : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Avellino : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Avellino : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
View More »
Bari : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Bari : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Bari : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Biella : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Biella : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bisceglie : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Bisceglie : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Bologna : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Bologna : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Bologna : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Brescia : 1241.20.39003 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Brescia : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Brescia : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Busto Arsizio : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Cagliari : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Cagliari : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Castellana Grotte : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Castellana Grotte : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Catania : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Catania : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Chieti : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Chieti : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Cisanello (pisa) : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Cisanello (Pisa) : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Cisanello (Pisa) : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Cuorgnè (to) : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Cuorgnè (to) : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Firenze : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Firenze : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Firenze : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Firenze : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Florence : Ospedale S. Annunziata
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Genova :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Genova : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Genova : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Gragnano : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Gragnano : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Livorno : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Livorno : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Marcianise : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Marcianise : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Messina :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Messina : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Messina : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Messina : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Milan : San Raffaele Hospital Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
Milan : San Raffaele Hospital, Dep. Infectious Diseases
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Milano : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Milano :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Milano : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Milano : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Milano : 1241.20.39002 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Milano : 1241.36.39022 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Milano : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Milano : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Milano : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Modena : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Modena : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Modena : Gastroenterology Unit
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
Modena : A.O.U. Policlinico Università di Modena e Reggio Emilia
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Modena : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Monserrato : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Monserrato : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Napoli : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Napoli :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Napoli : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Napoli : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Napoli : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Nocera Inferiore : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Nocera Inferiore : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Nola : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Nola : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Omegna (vb) : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Omegna (vb) : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Padova : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Padova : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Padova : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Padova : Az. Ospedaliera Universitaria di Padova
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Palermo : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Palermo : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Palermo : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Palermo : 1241.36.39020 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Parma : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Parma : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Parma : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pavia : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Piacenza : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Piacenza : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pisa : Updated
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
Pisa :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Pisa : Azienda Ospedaliero Universitaria Pisana
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Pisa : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Pisa : Azienda Ospedaliera Universitaria di Pisa. Ospedale di Cisanello
Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients
Pisa : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Reggio Calabria : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Reggio Calabria : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Roma : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Roma : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Roma : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Roma : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
San Giovanni Rotondo : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
San Giovanni Rotondo : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
San Giovanni Rotondo : Ospedale Casa Sollievo
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
San Giovanni Rotondo (fg) : 1241.36.39024 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Sassari : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Sassari : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Savona : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Savona : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Torino : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Torino : Az. Ospedaliera S.Giovanni Battista di Torino
Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients
Torino : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Torino : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Torrette Di Ancona : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Torrette Di Ancona : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Udine :
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression
Udine : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Udine : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Japan
Aichi : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Chiba, Chiba : 1220.48.8106 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Fukui : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Fukuoka : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Gunma : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
View More »
Hyogo : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Kagawa : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Kagoshima : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Kawasaki City : Toranomon Hospital
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
Kawasaki City : Toranomon Hospital
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
Kita-gun, Kagawa : 1220.48.8117 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Kitakyushu-shi : Local Institution
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Kurashiki, Okayama : 1220.48.8116 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Kurume, Fukuoka : 1220.48.8118 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Nagasaki : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Nagoya, Aichi : 1220.48.8113 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Nishinomiya, Hyogo : 1220.48.8114 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Oita : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Omura, Nagasaki : 1220.48.8119 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Osaka : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Saga : Local Institution
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Tanabe-shi : Local Institution
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Wakayama : GSK Investigational Site
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Korea, Republic of
Bucheon : Soon Chun Hyang University Bucheon Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Bucheon-Si : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Bucheon-si : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Busan :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Busan : Dong-A University Medical Center
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
View More »
Busan : Kosin University Gospel Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Busan : Inje University Haeundae Paik Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Busan : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Busan : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Busan-si : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Cheonan : Dankook University Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Chuncheon : Chuncheon Sacred Heart Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Chuncheon, Gangwon-Do :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Daegu : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Daegu : Kyungpook National University Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Daegu : Yeungnam University Medical Center
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Daegu : Kyungpook National University
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Daegu : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Daegu : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Guri : Hanyang University Guri Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Gyeongsangnam-Do :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Gyeongsangnam-Do : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Incheon :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Incheon : Gachon University Gil Hospital, Department of Pediatrics
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Incheon : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Jeju : Jeju National University Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Pusan : Pusan National University Yangsan Hospital (PNUYH)
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Pusan : 1220.48.8204 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Pusan : 1220.48.8205 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seongnam : SKChemicals
A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients
Seongnam : 1220.48.8203 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seoul : Seoul National University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Seoul St. Mary Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Severance Hospital, Yonsei University Health System
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Gangnam Severance Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Samsung Medical Center
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Korea University Guro Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Asan Medical Center
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Seoul : 1220.48.8207 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seoul : 1220.48.8202 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seoul : 1220.48.8206 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Seoul :
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Seoul :
Clinical Pharmacology Study of MP-424
Seoul : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Seoul : Hanyang University Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Inje University Sanggye Paik Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Kangbuk Samsung Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Kangdong Sacred Heart Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Kangnam Severance Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Konkuk University Medical Center
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Kyunghee university Medical Center
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Seoul : Severance Children's Hospital
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Seoul : Shinchon Severance Hospital
HBsAg Related Response Guided Therapy
Seoul : Seoul Metropolitan Government Boramae Medical Center
Histologic Changes and Noninvasive Assessments in HCV Patients With Peginterferon Alpha-2a Plus Ribavirin Therapy
Seoul : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Seoul : Department of clinical pharmacology and therapeutics
Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection
Seoul : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Sungnam : Bundang CHA medical center
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Suwon : Ajou University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Uijeongbu : Uijeongbu St.Mary's Hospital
A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)
Uijeongbu : Local Institution
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Wonju : Wonju Christian Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Yangsan : 1220.48.8201 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Yangsan : Busan National University Yangsan Hospital
Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.
Yangsan-si : Pusan National University Yangsan Hospital
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Kuwait
Safat : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Safat : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lebanon
Baabda : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Baabda : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Beirut : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Beirut : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Nabatieh : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
View More »
Nabatieh : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Tripoli : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Tripoli : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lithuania
Vilnius : UAB "Merck Sharp & Dohme"
A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)
Luxembourg
Luxembourg :
Telaprevir Open-Label Study in Co-Infected Patients
Macedonia, The Former Yugoslav Republic of
Skopje : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Skopje : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Malaysia
Petaling Jaya : MSD
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Mexico
Mexico City : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Mexico City : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Monterrey : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Moldova, Republic of
Chisinau : Arensia, Republican Clinical Hospital
A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
Kyiv : Merck Sharp & Dohme IDEA, Inc.
A Study to Evaluate Fine Needle Aspiration as a Method for MK-7009 Liver Pharmacokinetic Measurement in Participants With Chronic Hepatitis C (MK-7009-048)
Netherlands
Amsterdam :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Amsterdam : Academisch Medisch Centrum
GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Amsterdam : 1241.20.31001 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Amsterdam : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Amsterdam : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
View More »
Amsterdam : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Amsterdam : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Amsterdam Nl :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Leiden : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Leiden : Local Institution
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
Leiden : Local Institution
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
Maastricht : University of Maastricht
Ribavirin, Its Dosing Regime
Rotterdam : Erasmus Medical Center
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Rotterdam : Erasmus Medical Center
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
Rotterdam : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Rotterdam : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
New Zealand
Auckland : Auckland Clinical Studies
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Auckland : Merck Sharp & Dohme (New Zealand) Ltd.,
A Study of Different Doses of MK-5172 Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM1)
Auckland : Merck Sharp & Dohme (New Zealand) Ltd.,
A Study of Different Durations of Treatment With MK-5172 in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039 AM1)
Auckland :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Auckland : Updated
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
View More »
Auckland : Auckland Clinical Studies Ltd.
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Auckland : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Auckland : Merck Sharp & Dohme (New Zealand) Ltd.,
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Auckland : Merck Sharp & Dohme (New Zealand) Ltd.,
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172 (MK-5172-013 AM3)
Christchurch : Christchurch Hospital
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
Christchurch : Christchurch Clinical Studies Trust
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Christchurch : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Dunedin : Updated
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
Grafton : Auckland Clinical Studies
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Grafton : Aukland Clinical Studies
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Grafton :
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Grafton : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Grafton :
Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Hamilton : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Hamilton : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Rotorua : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Takapuna Auckland : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Wellington : GSK Investigational Site
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Norway
Oslo : Oslo/Akershus University hospitals
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Oman
Muscat : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Muscat : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Pakistan
Faisalabad : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Faisalabad : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Gujranwala : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Gujranwala : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Karachi : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
View More »
Karachi : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lahore : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Lahore : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Rawalpindi : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Rawalpindi : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Peru
La Victoria, Lima : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Lima : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Lima : Merck Sharp & Dohme, Peru S.R.L.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Philippines
Makati City : Merck Sharp & Dohme (I.A.) Corporation
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Poland
Bialystok :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Bialystok : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Bialystok : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Bydgoszcz : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Bydgoszcz : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
View More »
Bydgoszcz :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Bydgoszcz : Collegium Medicum Uniwersytet im. Mikołaja Kopernika
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Bydgoszcz :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Bydgoszcz :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Bytom :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Bytom :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Chorzow :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Chorzów :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Ciechanow :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Debica :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Katowice :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Kielce :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Koszalin :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Krakow : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Krakow : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Krakow :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Krakow : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Lancut :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Lancut :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Lodz :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Lodz : Updated
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
Mielec :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Myslowice :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Myslowice :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Myslowice :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Myslowice :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Poznan : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Pulawy :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Raciborz :
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Radom :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Szczecin : Samodzielny Publiczny Wojewódzki Szpital Zespolony
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Walbrzych :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Warsaw : Wojewódzki Szpital Zakaźny
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Warschau :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Warszawa :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Warszawa :
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Warszawa : MSD Polska Sp. Z o.o.
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (SCH503034-P07614 AM6)
Warszawa : MSD Polska Sp. Z o.o.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Wroclaw : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Wroclaw :
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
Wroclaw : Local Institution
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Wroclaw : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Wrocław : NZOZ Centrum Badan Klinicznych
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Portugal
Almada : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Almada : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Amadora : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Aveiro : 1220.48.3503 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Aveiro : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
View More »
Aveiro : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Aveiro : 1241.20.35103 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Barreiro : 1220.48.3509 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Coimbra : 1220.48.3506 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Faro : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Faro : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lisboa : 1220.48.3507 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Lisboa : 1220.48.3501 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Lisboa : 1220.48.3505 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Lisboa :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Lisboa : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Lisboa : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Lisboa : 1241.36.35101 Boehringer Ingelheim Investigational Site
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
Lisboa :
Telaprevir Open-Label Study in Co-Infected Patients
Lisboa N/A :
Telaprevir Open-Label Study in Co-Infected Patients
Paco D`arcos : Merck Sharp & Dohme Lda.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Porto : 1220.48.3502 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Porto : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Porto : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Porto : 1241.20.35102 Boehringer Ingelheim Investigational Site
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Porto :
Telaprevir Open-Label Study in Co-Infected Patients
Vila Real : 1220.48.3504 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Puerto Rico
Bayamon : Site Reference ID/Investigator# 70135
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Ponce : Site Reference ID/Investigator# 87033
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Ponce : Site Reference ID/Investigator# 70134
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Ponce : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
San Juan : Fundacion De Investigacion De Diego
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
View More »
San Juan :
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
San Juan : GSK Investigational Site
Dose Ranging of GSK2336805 in Combination Therapy
San Juan : Fundacion De Investigacion De Diego
Gilead Sustained Virologic Response (SVR) Registry
San Juan : Fundacion de Investigation de Diego
Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C
San Juan : Fundacion De Investigacion De Diego
Open-Label Study of GS-7977+ Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection
San Juan :
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
San Juan : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
San Juan : Local Institution
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
San Juan : Fundacion De Investigacion De Diego
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
San Juan : Local Institution
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
San Juan : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
San Juan : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Santurce :
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Santurce : Site Reference ID/Investigator# 78749
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Santurce : Site Reference ID/Investigator# 84593
A Study to Evaluate the Safety and Effect of ABT-450, Ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
Santurce : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Qatar
Doha : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Doha : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Romania
Brasov :
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
Bucharest : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Bucharest : 1220.48.4003 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bucharest : 1220.48.4004 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bucharest : 1220.48.4001 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
View More »
Bucharest : 1220.48.4002 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Bucharest : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Bucharest : Site Reference ID/Investigator# 70293
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bucharest : Site Reference ID/Investigator# 70294
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bucharest : Site Reference ID/Investigator# 70395
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bucharest : Site Reference ID/Investigator# 70396
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Bucharest : Grigore Alexandrescu Emergency Clinical Hospital for Children
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Bucharest : Fundeni Clinical Institute - Constantinesco
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Bucharest : National Institute of Infectious Diseases
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Bucharest : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Bucuresti : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Cluj-napoca : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Constanta : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Constanta : Clinical Infectious Diseases Hospital of Constanta
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Craiova : "Victor Babes" Clinical Hospital of Infectious Diseases and Pneumophtisology
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Iasi : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Iasi : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Iasi : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Timisoara : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Timisoara : Updated
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Timisoara : Updated
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
Timisoara : Local Institution
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
Russian Federation
Barnaul : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Chelyabinsk : 1220.48.7002 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Chelyabinsk : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Ekaterinburg : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Kaluga : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
View More »
Kaluga : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Kemerovo : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Khabarovsk : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Kirov : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Krasnodar : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Krasnoyarsk : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Lipetsk : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Loshkar-Ola :
Telaprevir Open-Label Study in Co-Infected Patients
Moscow : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Moscow : 1220.48.7001 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Moscow : 1220.48.7004 Boehringer Ingelheim Investigational Site
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Moscow : Updated
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
Moscow :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Moscow : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Moscow : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Moscow : Merck Sharp & Dohme IDEA, Inc.
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM1)
Moscow : Local Institution
Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Novokuznetsk : Local Institution
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection
Novosibirsk : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Perm :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Rostov-na-donu : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Ryazan : Updated
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)
Saint-Petersburg :
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Saint-Petersburg :
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Saint-Petersburg : Local Institution
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
